Bioequivalence Waivers: When the FDA Allows Generic Drugs to Skip Human Trials
January 3 2026
Tag: US biosimilars
21 Mar
Global Biosimilar Markets: Europe vs United States
Europe led the world in biosimilar adoption since 2006, while the U.S. lagged due to legal and regulatory hurdles. Now, with FDA rule changes and patent expirations, the U.S. market is accelerating rapidly. Both regions are saving billions in healthcare costs.
Read More...
